DESCRIPTION
Galactin-1 (Gal-1) is a small protein that has many therapeutic properties. Researchers at BYU discovered that recombinant human Gal-1 treatment improves membrane repair capacity, increases myogenic markers and decreases inflammation in dysferlin deficient myotubes, providing novel evidence regarding how Gal-1 favorably improves muscle function in limb girdle muscular dystrophy type 2B (LGMD2B).

PROBLEM SOLVED
Muscular dystrophy is a group of muscle diseases that gradually cause the muscles to weaken, leading to an increasing level of disability. The purpose of this invention is to state the role and therapeutic viability of Galectin-1 in muscular dystrophy and autoimmune diseases. Gal-1 has the potential to increase membrane repair capacity and shift immune homeostasis away from chronic inflammation.

KEY ADVANTAGES
» Improved therapeutic profile
» Enhanced therapeutic outcomes
» Effectual as a therapeutic in autoimmune diseases

APPLICATIONS
The main applications of this technology are in muscle dystrophy and autoimmune disorders.

Offer:
License
Exclusive
World Wide
All Fields of Use

IP Status:
Patent Pending

Lead Inventor
Dr. Pam Van Ry
PhD, Cellular and Molecular Pharmacology and Physiology

BYU #2019-015
Mike Alder
mike_alder@byu.edu
(801) 422-6266